Overview

A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions

Status:
Completed

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

The objective of this study was to assess bioequivalence of a potential generic 1 mg granisetron tablet formulation compared with Roche Laboratories' 1 mg granisetron tablet, Kytril, following a single 1 mg dose, under fed conditions.

Phase:

N/A

Details

Lead Sponsor:

Roxane Laboratories

Treatments:

Granisetron